Product Description
Mechanisms of Action: FGFR2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbisko
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ABSK121-NX-101 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-03-15 |
|
CTR20231152 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |